The aryl hydrocarbon receptor (AhR) has been shown to play important roles in the immune system, and contributions of AhR ligands to the differentiation and functions of Th17/Treg cells have recently been established. However, it has not been fully clarified whether AhR plays roles in B cell differentiation and functions. The environmental pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a highly potent AhR agonist, was reported to suppress the production of immunoglobulin M (IgM) in a transformed mouse B cell line. However, TCDD exhibits high toxicity toward cells and has unknown activities except for its action as an AhR agonist. In the present study, we tried to clarify how an endogenously generated AhR agonist affects mouse B cell differentiation and functions in terms of the direct effects on the expression of Ig subclasses in purified mouse B cells stimulated with an anti-CD40 antibody and interleukin-4. The AhR agonist 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), which is derived via tryptophan metabolism, suppressed the expression of not only IgM, but also IgG1 and IgE. ITE was also found to suppress the expression of secreted-type Ig mRNAs and plasma cell-specific genes. These findings indicate that the endogenous AhR agonist suppresses B cell differentiation into Ig-secreting plasma cells.
The aryl hydrocarbon receptor (AhR) is a liganddependent transcriptional regulator belonging to the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family. Upon ligand-mediated activation, AhR translocates into the nucleus and heterodimerizes with another bHLH/PAS protein known as aryl hydrocarbon nuclear translocator (ARNT). This AhR/ARNT complex binds to specific enhancer sequences adjacent to target promoters termed dioxin-responsive elements and enhances the transcriptional expression of target genes encoding phase I metabolic enzymes such as Cyp1a1 and Cyp1a2 (1, 19) . AhR is well known to mediate the toxic effects of environmental pollutants such as halogenated aromatic hydrocarbons (HAHs) and polyaromatic hydrocarbons (PAHs) (14, 25) . Therefore, AhR was originally regarded as a key regulator of xenobiotic metabolism. Previous analyses of AhR-null mice indicated that AhR also has physiological roles in the immune system, liver vasculature development and successful reproduction (4, 6, 14) . More recently, some reports have indicated that AhR plays significant roles in Treg and Th17 cell differentiation in a ligandspecific manner (16, 23) . In these papers, a highly potent AhR agonist, 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD), was shown to enhance Treg and Th17
AhR agonists suppress B cell differentiation into Ig-secreting plasma cells via the downregulation of plasma cell-specific molecules.
MATERIALS AND METHODS
Mice. C57BL/6N mice were purchased from Charles River Japan (Kanagawa, Japan) and used at 7-10 weeks of age. The mice used in the present study were maintained in specific pathogen-free conditions according to the guidelines of the Experimental Animal Facility at Hokkaido University.
Reagents. ITE and CH223191 were synthesized by Japan Tobacco Inc. (Osaka, Japan). An anti-mouse CD40 monoclonal antibody (HM40-3) was purchased from BD Pharmingen (San Diego, CA). Recombinant murine IL-4 was purchased from PeproTech EC (London, England).
B cell isolation and cell culture. Enriched populations of splenic B cells were obtained using a Mouse B Cell Isolation Kit (Miltenyi Biotec, Foster City CA) according to the manufacturer's protocol. The purified mouse B cells were cultured in RPMI1640 medium supplemented with 10% fetal calf serum, 100 U/mL penicillin and 100 mg/mL streptomycin, and incubated at 37°C under 5% CO 2 in a humidified atmosphere in 96-well flat-bottom plates.
Enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunospot (ELISPOT) assay.
Purified mouse B cells were plated at 2 × 10 4 cells/well in 96-well plates and treated with various concentrations of ITE or CH223191 in the presence of the anti-CD40 antibody and IL-4 for 6 days. The concentrations of IgM, IgG1 and IgE in the culture supernatants were measured using Mouse IgM, IgG1 and IgE ELISA Quantitation kits (Bethyl Laboratories, Montgomery, TX) according to the manufacturer's protocol. The frequency of IgG1 antibody-secreting cells (ASCs) was determined by the ELISPOT technique. MultiScreen 96-well filtration plates (Millipore, Billerica, MA) were coated with an anti-mouse IgG1 antibody (Bethyl Laboratories). B cells were then plated at 3 × 10 4 cells/well in the precoated filter plates and incubated at 37°C in a CO 2 incubator overnight. The cells were removed with phosphatebuffered saline containing 0.05% Tween 20. Spots derived from IgG1-ASCs were detected with a biotin-conjugated anti-mouse IgG1 antibody (A85-1; BD Pharmingen) and streptavidin-horseradish peroxidase, and visualized with an ELISPOT Blue Color cell differentiation. Another paper indicated that natural agonists for AhR in the culture medium were essential for optimal differentiation of Th17 cells, and that a synthetic AhR antagonist, CH223191, suppressed Th17 cell differentiation (22) . Furthermore, a synthetic AhR agonist, M50367, was found to act directly on naïve Th cells to inhibit their differentiation into Th2 cells (13) . These data suggest that AhR plays a pivotal role in T cell differentiation.
On the other hand, little is known about whether AhR plays a role in B cell differentiation. To date, it has been reported that TCDD has the negative effects on humoral immunity (3, 21) . In some papers, treatment with TCDD was shown to suppress IgE production in a mouse model and also to inhibit IgM production in a transformed mouse cell line (7, 20, 21) . These reports indicated that AhR may be related to B cell differentiation, but its mechanism remains unknown. Although TCDD was widely used as an AhR agonist in these previous studies, it is important to note that TCDD causes several disorders in cells and animals (3, 21) . For these reasons, the use of a non-toxic AhR ligand may be preferable as an experimental tool to investigate the primary role of AhR in B cell differentiation. Therefore, we used 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), a metabolite of tryptophan, as an endogenous and non-toxic agonist for AhR (8) . ITE and TCDD were reported to elicit the same immediate changes in gene expression in mouse lung fibroblasts (5) . Furthermore, as a reference compound, we tried to use an AhR antagonistic compound. Several AhR antagonists, such as flavones and resveratrol, have AhR antagonist activity at low concentrations, but AhR agonist activity at high concentrations (25) . In contrast, the synthetic AhR antagonist CH223191 has no AhR agonist activity at concentrations up to 100 μM (10) . For this reason, we used CH223191 as an AhR antagonist in this study.
In the present study, we investigated whether AhR ligands have direct effects on purified mouse B cell differentiation under T cell-dependent humoral conditions. We found that the AhR agonist ITE suppressed the production of IgM, IgG1 and IgE in purified mouse B cells stimulated with interleukin (IL)-4 and an anti-CD40 antibody. Furthermore, ITE had little effect on class switching, but suppressed B cell differentiation from naïve B cells into Ig-secreting plasma cells. In addition, ITE suppressed the expression of some plasma cell-specific genes at the transcriptional level. These findings indicate that
RESULTS

Direct effects of AhR ligands on the production of IgM, IgG1 and IgE in purified mouse B cells
Although it has been reported that treatment with TCDD suppresses IgE production in a mouse model, its mechanism remains unknown. In the present study, we used a non-toxic natural AhR agonist, ITE, which is a metabolite of tryptophan. In addition, we used a pure antagonist, CH223191, which does not possess agonistic activity at high concentrations. Furthermore, we used treatments with an anti-CD40 antibody and IL-4 for stimulation of B cells, which trigger a T cell-dependent B cell response and can induce class switching to IgG1 and IgE in mouse B cells. As shown in Fig. 1 , treatment with ITE had no effect on the mRNA expression of AhR, but strongly enhanced the mRNA expression of Cyp1a1 in mouse splenic B cells stimulated with the anti-CD40 antibody and IL-4 for 6 days. On the other hand, treatment with CH223191 had no effects on the mRNA expression of AhR and Cyp1a1 at concentrations up to 1 μM. Next, we investigated the effects of AhR ligands on the production of immunoglobulins in mouse splenic B cells. As shown in Fig. 2 , treatment of mouse B cells with ITE suppressed IgM, IgG1 and IgE production in a dose-dependent manner. On the other hand, treatment with CH223191 showed a tendency to enhance the production of IgG1 and had little effect on the production of IgM and IgE. These findings suggest that AhR ligands directly affect B cell function.
Effects of AhR ligands on the expression of GLTs and class switch-related genes
To determine whether AhR ligands have effects on immunoglobulin class switching in mouse B cells under anti-CD40 antibody and IL-4 stimulation, we examined the ability of ITE or CH223191 to suppress the expression of γ1GLT and εGLT, which are necessary to target a switch region for recombination and switching. As shown in Fig. 3A and B, treatment of mouse B cells with ITE or CH223191 did not significantly affect the expression of γ1GLT and εGLT. Furthermore, we examined the ability of the AhR ligands to suppress the expression of two class switch-related genes, AID and UNG. As shown in Fig. 3C and D, treatment of mouse B cells with ITE or CH223191 did not suppress the expression of AID and UNG mRNAs. These findings indicate that AhR ligands have no effects on class switching in B Module (R&D Systems, Minneapolis, MN). IgG1-ASCs were analyzed with a CTL ImmunoSpot 3 Analyzer (Cellular Technology Ltd., Cleveland, OH). Statistical analysis. The results were evaluated by Dunnett's test for multiple comparisons using StatLight 1998 (Yukms Corp., Tokyo, Japan). Differences vs. the DMSO-treated groups were considered to be significant for values of P < 0.05.
Quantitative RT-PCR (qRT-PCR).
to suppress the differentiation into IgG1-ASCs by ELISPOT analysis. As shown in Fig. 5 , treatment of mouse B cells with ITE reduced the number of IgG1-ASCs, whereas treatment with CH223191 elevated the number of IgG1-ASCs. These findings demonstrate that ITE suppresses the B cell differentiation into antibody-secreting plasma cells, while CH223191 enhances rather than suppresses the B cell differentiation.
Effects of AhR ligands on the expression of differentiation-related transcriptional regulators and a marker gene
To determine how AhR ligands affect the plasma cell differentiation of mouse B cells under anticell differentiation.
Effects of AhR ligands on plasma cell differentiation of mouse B cells
To determine whether AhR ligands affect the plasma cell differentiation of mouse B cells under anti-CD40 antibody and IL-4 stimulation, we examined the effects of ITE or CH223191 on the expression of membrane-type and secreted-type Ig mRNAs by qRT-PCR analysis. As shown in Fig. 4 , treatment of mouse B cells with ITE had little effect on the expression of membrane-type IgG1 and IgE mRNAs. Interestingly, treatment with ITE markedly suppressed the expression of secreted-type IgG1 mRNA and showed a tendency to suppress the expression of secreted-type IgE mRNA. On the other hand, treatment with CH223191 did not significantly affect the expression of membrane-type and secretedtype IgG1 or IgE mRNAs. To further determine whether AhR ligands suppress the plasma cell differentiation of mouse B cells under anti-CD40 antibody and IL-4 stimulation, we examined the ability of ITE or CH223191 Fig. 2 Effects of the AhR ligands on the production of immunoglobulins in mouse splenic B cells. Purified mouse splenic B cells were treated with the indicated concentrations of ITE or CH223191 in the presence of an anti-CD40 antibody (0.3 μg/mL) and IL-4 (7.5 ng/mL) for 6 days. The amounts of IgM (A), IgG1 (B) and IgE (C) were determined by ELISA. Results represent the mean ± SD of triplicate determinations in each treatment group from three separate experiments. *P < 0.05, **P < 0.01, vs. the DMSO-treated group. 4 mRNA expression levels of membrane-type and secreted-type immunoglobulins in mouse splenic B cells. Purified mouse splenic B cells were treated with the indicated concentrations of ITE or CH223191 in the presence of an anti-CD40 antibody (0.3 μg/mL) and IL-4 (7.5 ng/mL) for 6 days. The expression levels of membrane-type IgG1 (A), membrane-type IgE (B), secreted-type IgG1 (C) and secreted-type IgE (D) were determined by qRT-PCR analysis. The relative expression levels of each gene were normalized by the expression levels of GAPDH. Results represent the mean ± SD of quadruplicate determinations in each treatment group from two separate experiments. **P < 0.01, vs. the DMSO-treated group.
marker Syndecan-1. Also, treatment with CH223191 showed a tendency to enhance the XBP-1 and Syndecan-1 expression. However, treatment with ITE or al regulator Blimp-1, but showed a tendency to suppress the expression of another plasma cell-specific transcriptional regulator XBP-1, and the plasma cell ferentiation into Ig-secreting plasma cells, the molecular mechanism is poorly understood. It has been reported that many transcriptional regulators constitute the gene network that controls the transition of B cells into plasma cells transition (15) . In the network, Blimp-1 and XBP-1 are transcriptional regulators that promote Ig-secreting plasma cells. TCDD treatment was found to suppress the expression of Blimp-1 and XBP-1 in the LPS-stimulated mouse B cell line CH12.LX (21) . In the present study, we showed that ITE suppressed the expression of XBP-1 mRNA in mouse B cells stimulated with an anti-CD40 antibody and IL-4. XBP-1 is a basic-region leucine zipper protein belonging to the ATF/CREB family of transcription factors, and is essential for B cell differentiation into plasma cells (17, 18) . ITE may mainly affect B cell differentiation into Igsecreting plasma cells by suppressing the expression of XBP-1 at the transcriptional level, but its precise mode of action remains elusive. Some papers have reported that TCDD treatment impaired the downregulation of Pax5, which is a repressor of B cell differentiation and a transcriptional repressor of XBP-1 (21, 24) . In contrast, we observed that there was no change in the expression of Pax-5 mRNA in ITE-treated mouse B cells. Thus, it remains unclear whether Pax-5 plays a pivotal role in suppressing B cell differentiation by endogenous AhR agonists. We are now investigating whether other AhR agonists and antagonists have effects on B cell differentiation and analyzing their modes of action. Elucidation of the inhibitory mechanism for B cell differentiation by AhR agonists may be useful for the development of B cell-targeted therapies for autoimmune diseases and allergy.
CH223191 had no effect on the expression of Pax-5, which is a transcriptional master regulator in B cell development and represses the expression of plasma cell-specific transcriptional factors. These findings indicate that AhR ligands affect the B cell differentiation by regulating the expression of plasma cellspecific transcriptional regulators in mouse B cells.
DISCUSSION
In this study, we have shown that ITE, as an endogenous and non-toxic AhR agonist, suppressed the production of IgM, IgG1 and IgE in purified mouse B cells stimulated with IL-4 and an anti-CD40 antibody. In addition, our data indicated that ITE inhibited B cell differentiation into Ig-producing plasma cells. In previous papers, the highly potent AhR agonist TCDD was shown to suppress the production of IgM in human B cells and a lipopolysaccharide (LPS)-induced transformed mouse B cell line, CH12.LX, and to inhibit the differentiation into Igproducing plasma cells (11, 12, 20, 21) . More recently, it was reported that benzo[a]pyrene also suppressed the differentiation into plasma cells in human B cells (2) . In agreement with these previous reports, our results indicated that the endogenous and non-toxic agonist ITE was also able to suppress the differentiation of mouse naïve B cells into Igproducing plasma cells among purified mouse splenic B cells stimulated with an anti-CD40 antibody and IL-4. These findings suggest that endogenous AhR agonists can directly play a significant role in B cell differentiation. On the other hand, we found that a synthetic AhR antagonist, CH223191, had a tendency to enhance the production of IgG1 in this study. These findings indicate that endogenous AhR agonists may play a role in B cell differentiation. CH223191 may be able to antagonize the binding of endogenous AhR ligands in B cell differentiation. However, special attention should be paid to this interpretation. Recently, it was reported that CH223191 is a ligand-selective antagonist of AhR, and preferentially inhibits the ability of some classes of AhR agonists (TCDD and related HAHs), but not others (PAHs, flavonoids or indirubin), to activate the AhR and AhR signal transduction (26) . However, the important point to note is that this AhR agonist had the ability to suppress the production of several immunoglobulins. These findings suggest the possibility that immunoglobulin production from B cells may be able to be controlled using synthetic AhR ligands. Although some AhR agonists suppress B cell dif-
